Search Thermo Fisher Scientific
Explore the Oncomine Comprehensive Assay v3
The Ion Torrent Oncomine Comprehensive Assay v3 on the Genexus System will enable you to:
Rapidly analyze relevant SNVs, indels, CNVs, and gene fusions from 161 genes. This allows you to report relevant biomarkers for key cancer types, including breast, colorectal, lung, ovarian, prostate, and others as soon as the next day and integrate them with immunohistochemistry results.
Save your technicians’ time with a highly automated workflow, offering a hands-on time of as little as 20 minutes.
Reduce complexity and cost of implementation and maintenance by utilizing a true end-to-end solution, from sample to report, without the need for additional bioinformatics expertise.
Generate results from 20 ng of DNA and 20 ng of RNA, enabling you to obtain results from small and low-quality FFPE samples, such as NSCLC or prostate cancer samples.
On Demand Webinar: Evaluation Of Oncomine Comprehensive Assay v3
Watch our OCA v3 webinar to discover how the Genexus System enables rapid NGS testing, featuring Dr. Bin Wang from SydPath-St. Vicent's Hospital in Sydney, Australia.
End-to-end ngs solution
With only two touchpoints and as little as 20 minutes of hands-on time, the Oncomine Comprehensive Assay v3 on the Genexus System reduces laboratory staff burden and the potential for human errors and alleviates the need for specialized bioinformatics expertise by automating nucleic acid extraction and quantification, library preparation, sequencing, and analysis.
The Oncomine Comprehensive Assay v3 can start from FFPE on the Genexus Purification System or from purified nucleic acid on the Genexus Integrated Sequencer. Types of runs include DNA- or RNA-only, or DNA and RNA simultaneously.
NGS systems
The Oncomine Comprehensive Assay v3 is available on the Genexus System and additionally available for use on the Ion GeneStudio S5 System with manual or automated library preparations.
Relevant biomarkers in precision oncology research across multiple tumors
The Oncomine Comprehensive Assay v3 covers the most relevant biomarkers for precision oncology research. This includes SNVs, indels, CNVs, and gene fusions from 161 genes encompassing cancer drivers and tumor suppressors. A subset of genes included in the panel are shown in the figure.
As DNA damage repair genes are becoming particularly relevant in multiple cancers including breast, ovarian, prostate, and pancreatic, the Oncomine Comprehensive Assay v3 includes genes in the homologous recombination repair (HRR) pathway, including ATM, BRCA1, BRCA2, CDK12, CHEK1, CHEK2, PALB2, RAD51B, RAD51C, and RAD51D, among others, enabling simultaneous analysis of HRR genes using a single workflow.
Gene coverage
| Hotspot genes | Full-length genes | Copy number genes | Gene fusions (inter-and intra-genetic) | ||||||
| AKT1 | FGFR4 | MED12 | SRC | ARID1A | PALB2 | AKT1 | MDM2 | AKT2 | NF1 |
| AKT2 | FLT3 | MET | STAT3 | ATM | PIK3R1 | AKT2 | MDM4 | ALK | NOTCH1 |
| AKT3 | FOXL2 | MTOR | TERT | ATR | PMS2 | AKT3 | MET | AR | NOTCH4 |
| ALK | GATA2 | MYC | TOP1 | ATRX | POLE | ALK | MYC | AXL | NRG1 |
| AR | GNA11 | MYCN | U2AF1 | BAP1 | PTCH1 | AR | MYCL | BRAF | NTRK1 |
| ARAF | GNAQ | MYD88 | XPO1 | BRCA1 | PTEN | AXL | MYCN | BRCA1 | NTRK2 |
| AXL | GNAS | NFE2L2 | BRCA2 | RAD50 | BRAF | NTRK1 | BRCA2 | NTRK3 | |
| BRAF | H3F3A | NRAS | CDK12 | RAD51 | CCND1 | NTRK2 | CDKN2A | NUTM1 | |
| BTK | HIST1H3B | NTRK1 | CDKN1B | RAD51B | CCND2 | NTRK3 | EGFR | PDGFRA | |
| CBL | HNF1A | NTRK2 | CDKN2A | RAD51C | CCND3 | PDGFRA | ERBB2 | PDGFRB | |
| CCND1 | HRAS | NTRK3 | CDKN2B | RAD51D | CCNE1 | PDGFRB | ERBB4 | PIK3CA | |
| CDK4 | IDH1 | PDGFRA | CHEK1 | RB1 | CDK2 | PIK3CA | ERG | PPARG | |
| CDK6 | IDH2 | PDGFRB | CREBBP | RNF43 | CDK4 | PIK3CB | ESR1 | PRKACA | |
| CHEK2 | JAK1 | PIK3CA | FANCA | SETD2 | CDK6 | PPARG | ETV1 | PRKACB | |
| CSF1R | JAK2 | PIK3CB | FANCD2 | SLX4 | EGFR | RICTOR | ETV4 | PTEN | |
| CTNNB1 | JAK3 | PPP2R1A | FANCI | SMARCA4 | ERBB2 | TERT | ETV5 | RAD51B | |
| DDR2 | KDR | PTPN11 | FBXW7 | SMARCB1 | ESR1 | FGFR1 | RAF1 | ||
| EGFR | KIT | RAC1 | MLH1 | STK11 | FGF19 | FGFR2 | RB1 | ||
| ERBB2 | KNSTRN | RAF1 | MRE11A | TP53 | FGF3 | FGFR3 | RELA | ||
| ERBB3 | KRAS | RET | MSH2 | TSC1 | FGFR1 | FGR | RET | ||
| ERBB4 | MAGOH | RHEB | MSH6 | TSC2 | FGFR2 | FLT3 | ROS1 | ||
| ERCC2 | MAP2K1 | RHOA | NBN | FGFR3 | JAK2 | RSPO2 | |||
| ESR1 | MAP2K2 | ROS1 | NF1 | FGFR4 | KRAS | RSPO3 | |||
| EZH2 | MAP2K4 | SF3B1 | NF2 | FLT3 | MDM4 | TERT | |||
| FGFR1 | MAPK1 | SMAD4 | NOTCH1 | IGF1R | MET | ||||
| FGFR2 | MAX | SMO | NOTCH2 | KIT | MYB | ||||
| FGFR3 | MDM4 | SPOP | NOTCH3 | KRAS | MYBL1 | ||||
Ordering information
For Ion GeneStudio S5 System
For Genexus System
Featured resources
For Research Use Only. Not for use in diagnostic procedures.